Table 1.
Patient characteristics at diagnosis
| |
Combined group |
|
EBRT + Boost |
SBRT alone |
|
|---|---|---|---|---|---|
| Age at diagnosis | No. patients (%) | P value | No. patients | No. patients | |
| |
40-49 |
1 (1.0) |
|
0 |
1 |
| |
50-59 |
13 (13.4) |
|
9 |
4 |
| |
60-69 |
31 (32.0) |
|
12 |
19 |
| |
70-79 |
39 (40.2) |
|
20 |
19 |
| |
80-89 |
13 (13.4) |
|
4 |
9 |
| Mean (range) |
|
70.0 (43.2-85.7) |
0.039 |
69.5 (50.6-84.4) |
70.3 (43.2-85.7) |
| PSA level at treatment |
|
ng/mL |
|
|
|
| Combined |
Mean (range) |
14.4 (0.59-53.1) |
|
14.7 |
14.2 |
| |
Median |
11.5 |
0.0056 |
12 |
11.25 |
| PSA level at diagnosis |
|
No. patients |
|
|
|
| |
<4 ng/mL |
5 (5.2) |
|
1 |
4 |
| |
4-10 ng/mL |
30 (30.9) |
|
17 |
13 |
| |
>10-20 ng/mL |
39 (40.2) |
|
16 |
23 |
| |
>20 ng/mL |
23 (23.7) |
|
11 |
12 |
| Clinical stage |
|
|
|
|
|
| |
T1c |
73 (75.2) |
0.22 |
33 |
40 |
| |
T2x |
2 (2.1) |
|
2 |
0 |
| |
T2a |
18 (18.6) |
|
6 |
12 |
| |
T2b |
2 (2.1) |
|
2 |
0 |
| |
T2c |
2 (2.1) |
|
2 |
0 |
| Gleason score |
|
|
0.55 |
|
|
| |
6 |
4 (4.1) |
|
1 |
3 |
| |
7 (3 + 4) |
15 (15.5) |
|
7 |
8 |
| |
7 (4 + 3) |
16 (16.5) |
|
7 |
9 |
| |
8 |
46 (47.4) |
|
22 |
24 |
| |
9 |
16 (16.5) |
|
8 |
8 |
| Hormone treatment |
|
|
0.34 |
|
|
| |
No |
43 (44.3) |
|
17 |
26 |
| |
Yes |
54 (55.7) |
|
28 |
26 |
| RT treatment |
|
|
0.86 |
|
|
| |
SBRT |
52 (53.6) |
|
|
|
| |
EBRT + SBRT |
45 (46.4) |
|
|
|
| High risk assessment: criteria |
|
|
0.95 |
|
|
| Gleason ≥ 8 or PSA > 20 |
|
83 (85.6) |
|
45 |
38 |
| Multiple adverse factors*: | 14 (14.4) | 0 | 14 | ||
*Per NCCN 2013, patients with multiple adverse factors can be shifted into the high risk group (T2b-T2c, Gleason score 7, PSA 10–20 ng/mL).